Peripheral artery disease, the ‘lost syndrome’ during lockdown for COVID‑19: A report of three cases
- Chiara Panzavolta
- Beniamino Zalunardo
- Sandro Irsara
- Luca Ferretto
- Adriana Visonà
Affiliations: Angiology Unit, Azienda ULSS 2 Marca Trevigiana, Castelfranco Veneto, I-31033 Treviso, Italy, Department of Vascular Surgery, Azienda ULSS 1 Dolomiti, I-32100 Belluno, Italy
- Published online on: September 16, 2021 https://doi.org/10.3892/mi.2021.15
Copyright: © Panzavolta
et al. This is an open access article distributed under the
terms of Creative
Commons Attribution License.
Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )
This article is mentioned in:
The recent coronavirus disease 2019 (COVID‑19) pandemic has significantly increased the burden placed on healthcare systems worldwide. This health emergency has led to changes being implemented in the organization of health institutions and has shifted the focus on pandemic management. This has led to marked changes being made in the treatment of patients without COVID‑19, and has resulted in more difficult access to healthcare, with ensuing delays in diagnosis and treatment. Vascular diseases, including peripheral artery disease (PAD), require prompt treatment in the majority of cases in order to save affected limbs. Moreover, COVID‑19 may result in acute arterial and venous complications, which need to be promptly recognized and treated. The present study describes three paradigmatic clinical cases of hospitalized patients, which are representative of the different forms of the ‘lost syndrome’ caused by either the direct effect of COVID‑19 or by the effects of COVID‑19 on the healthcare system and lifestyle factors. Prophylaxis against arterial and venous thrombotic events is crucial in patients with COVID‑19, particularly those with a marked inflammatory state. On the other hand, the COVID‑19 pandemic has diminished the access to healthcare system for patients with other chronic pathologies, with potential severe consequences for vulnerable patient groups, such as those with PAD and cardiovascular diseases. For these patients, the authors' experience over the last few months suggests that more suitable measures need to be adopted to avoid additional severe consequences on public health. In addition, it is necessary to identify pathways that will allow these patients to have rapid access to treatment with marked improvements in outcome.